Cisplatin-loaded core cross-linked micelles: Comparative pharmacokinetics, antitumor activity, and toxicity in mice

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2557-2571

  Oberoi, Hardeep S ^a   Nukolova, Natalia V ^a,b   Laquer, Frederic C ^c   Poluektova, Larisa Y ^d   Huang, Jiangeng ^a   Alnouti, Yazen ^a   Yokohira, Masanao ^e   Arnold, Lora L ^e   Kabanov, Alexander V ^a,b   Cohen, Samuel M ^e   Bronich, Tatiana K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Block ionomer complex; Cisplatin; Cross linked micelle; Drug delivery; Ovarian cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; MACROGOL; NITROGEN; POLYMETHACRYLIC ACID; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS LINKING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TISSUE LEVEL; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MICELLE; MOUSE; NONHUMAN; OVARY CANCER; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG CARRIERS; FEMALE; HEMOLYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; MICELLES; NANOMEDICINE; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84870361745     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S29145     Document Type: Article

References (34)

1. Gordon M, Hollander S. Review of platinum anticancer compounds. J Med. 1993;24(4-5):209-265.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573-584.
3. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev. 1998;24(4): 265-281.
4. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4(6):889-901.
5. Calvert H, Judson I, van der Vijgh WJF. Platinum complexes in cancer medicine-pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv. 1993;17: 189-217.
6. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol. 2007;63(1):12-31.
7. Haxton KJ, Burt HM. Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci. 2009;98(7):2299-2316.
8. Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR. Advances in platinum chemotherapeutics. Chemistry. 2010;16(24):7064-7077.
9. Bontha S, Kabanov AV, Bronich TK. Polymer micelles with crosslinked ionic cores for delivery of anticancer drugs. J Control Release. 2006;114(2):163-174.
10. Nishiyama N, Yokoyama M, Aoyagi T, Okano T, Sakurai Y, Kataoka K. Preparation and characterization of self-assembled polymer-metal complex micelle from cis-dichlorodiammineplatinum(II) and poly(ethylene glycol)-poly(alpha, beta-aspartic acid) block copolymer in an aqueous medium. Langmuir. 1999;15(2):377-383.
11. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces. 1999;16(1-4):3-27.
12. Rosler A, Vandermeulen GWM, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev. 2001;53(1):95-108.
13. Nukolova NV, Oberoi HS, Cohen SM, Kabanov AV, Bronich TK. Folatedecorated nanogels for targeted therapy of ovarian cancer. Biomaterials. 2011;32(23):5417-5426.
14. Oberoi HS, Laquer FC, Marky LA, Kabanov AV, Bronich TK. Core cross-linked block ionomer micelles as pH-responsive carriers for cis-diamminedichloroplatinum(II). J Control Release. 2011;153(1): 64-72.
15. Kim JO, Kabanov AV, Bronich TK. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009;20:197-204.
16. Kim JO, Sahay G, Kabanov AV, Bronich TK. Polymeric micelles with ionic cores containing biodegradable cross-links for delivery of chemotherapeutic agents. Biomacromolecules. 2010;11(4):919-926.
17. Bronich TK, Keifer PA, Shlyakhtenko LS, Kabanov AV. Polymer micelle with cross-linked ionic core. J Amer Chem Soc. 2005;127(23): 8236-8237.
18. King FG, Dedrick RL. Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse. J Pharmacokinet Biopharm. 1992;20(1):95-99.
19. Gaymalov ZZ, Yang ZZ, Pisarev VM, Alakhov VY, Kabanov AV. The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials. 2009;30(6):1232-1245.
20. McIntosh DP, Cooke RJ, McLachlan AJ, Daley-Yates PT, Rowland M. Pharmacokinetics and tissue distribution of cisplatin and conjugates of cisplatin with carboxymethyldextran and A5B7 monoclonal antibody in CD1 mice. J Pharm Sci. 1997;86(12):1478-1483.
21. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1-7.
22. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1): 409-422.
23. Kim JO, Nukolova NV, Oberoi HS, Kabanov AV, Bronich TK. Block ionomer complex micelles with cross-linked cores for drug delivery. Polym Sci Ser A Chem Phys. 2009;51(6):708-718.
24. Sahay G, Kim JO, Kabanov AV, Bronich TK. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials. 2010;31(5):923-933.
25. Levi FA, Hrushesky WJ, Halberg F, Langevin TR, Haus E, Kennedy BJ. Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol. 1982;18(5):471-477.
26. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-360.
27. Waser PG, Muller U, Kreuter J, et al. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int J Pharm. 1987;39(3):213-227.
28. Souris JS, Lee CH, Cheng SH, et al. Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials. 2010;31(21):5564-5574.
29. Cho M, Cho WS, Choi M, et al. The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett. 28 2009;189(3):177-183.
30. Basinger MA, Jones MM, Holscher MA. L-methionine suppresses pathological sequelae of cis-platinum in the rat. Fundam Appl Toxicol. 1990;14(3):568-577.
31. Milicevic Z, Slepcevic V, Nikolic D, Zivanovic V, Milicevic NM. Effects of cis-diamminedichloroplatinum-II (cisplatin) on the splenic tissue of rats-a histoquantitative study. Exp Mol Pathol. 1994;61(2): 77-81.
32. Xue YK, Tang XX, Huang J, et al. Anti-tumor efficacy of polymerplatinum(II) complex micelles fabricated from folate conjugated PEG-graft-alpha, beta-poly [(N-amino acidyl)-aspartamide] and cis-dichlorodiammine platinum(II) in tumor-bearing mice. Colloids Surf B Biointerfaces. 2011;85(2):280-288.
33. Paraskar AS, Soni S, Chin KT, et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A. 2010;107(28):12435-12440.
34. Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol. 2011;6(12):815-823.